Sponsored by the AAPS GCTPs Bioanalysis and Biomarker Subteam
Monday, June 27, Noon to 1 pm EST
Open Scientific Panel Discussion: IMG strategy for Cell Therapy and clinical application
- How IMG study results were used and what are the value in approved products?
- Timing of monitoring/sample collection for cellular responses
- Identify our current limitations
- Better practice in future studies, any changes?
- New modality/generation of CART IMG assessment
- Current IMG draft guidance (FDA and EMA) for cell therapy
------------------------------
Vibha Jawa
Executive Director
Nonclinical Disposition and Bioanalysis
Bristol-Myers Squibb
Princeton,NJ
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------